Patient treatment satisfaction after switching to NovoMixA® 30 (BIAsp 30) in the IMPROVE™ study: an analysis of the influence of prior and current treatment factors
Patient treatment satisfaction after switching to NovoMixA® 30 (BIAsp 30) in the IMPROVE™ study: an analysis of the influence of prior and current treatment factors
复制标题
DOI：
10.1007/s11136-010-9699-0
复制
发表时间：
2010-11-01
影响因子：
3.5
通讯作者：
Christensen, Torsten L.
中科院分区：
文献类型：
--
作者：
Brod, Meryl;Valensi, Paul;Christensen, Torsten L.
随着治疗选择的增加，了解糖尿病的治疗满意度(TS)变得越来越重要。这项研究在一项观察性研究中检查了NovoMix(A(R))30对2型糖尿病患者的治疗满意度。DiabMedSat评估总体、治疗负担、症状和疗效治疗满意度。在基线和第26周用方差分析检验不同类型的预处理变量对TS的影响。用t检验和效应大小检验患者第26周的满意度。线性回归模型考察了先前治疗因素(年龄、性别、糖尿病病程、先前治疗类型和糖尿病相关并发症)和当前治疗因素(体重增加、低血糖事件、达到治疗目标)对TS的影响。数据集包括17,488人。先前的胰岛素治疗对基线满意度有更积极的影响。在26周时，两组患者在总体、症状和负荷TS方面没有差异。目前使用NovoMix 30的治疗显著改善了TS。回归分析检查了治疗前因素和当前治疗因素的联合作用，发现除年龄影响因素外，所有因素都影响TS，尽管影响范围不同。接受NovoMix 30治疗的患者报告治疗满意度提高，这一改善被认为对患者具有临床意义。
Understanding treatment satisfaction (TS) for diabetes is increasingly important as treatment options increase. This study examines treatment satisfaction with NovoMix(A (R)) 30 in an observational study in patients with type 2 diabetes.The DiabMedSat assesses Overall, Treatment Burden, Symptom and Efficacy Treatment Satisfaction. The impact of type of pretreatment variables on TS was examined by ANOVA at baseline and week 26. Satisfaction at week 26 was examined by t-test and effect size. Linear regression models examined impact of prior treatment factors (age, gender, duration of diabetes, type of prior treatment and diabetes-related comorbidities) and current treatment factors (weight gain, hypoglycemic events, reaching therapeutic goal) on TS.The data set comprised 17,488 persons. Prior treatment with insulin had a more positive impact on baseline satisfaction. At week 26, there were no differences between type of prior treatment groups in Overall, Symptoms and Burden TS. Current treatment with NovoMix 30 significantly improved TS. Regression analyses examining the combined effect of pretreatment factors and current treatment factors found that all factors except for age-impacted TS although the domains impacted varied.Patients treated with NovoMix 30 reported improved treatment satisfaction, and the improvement is considered clinically meaningful to patients.